Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
about
Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapyClinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting.Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionNevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South AfricaFactors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAARTOccult hepatitis B virus coinfection in HIV-positive African migrants to the UK: a point prevalence study.Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.Comorbidities among HIV-infected injection drug users in Chennai, India.Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in CambodiaChallenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited SettingsEfficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsMulticenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Review of tenofovir-emtricitabine.Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.Adverse effects of highly active antiretroviral therapy in developing countries.Idiosyncratic drug-induced liver injury: an overview.Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, EthiopiaChanges to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trialHBV infection in untreated HIV-infected adults in Maputo, Mozambique.Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report.Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy.Molecular characterization of hepatitis B virus strains circulating in Belgian patients co-infected with HIV and HBV: overt and occult infection.Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database.Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3
P2860
Q28488149-6BB844D1-2F38-47A8-8D8E-B1C921E0883BQ33390898-7A21F512-C9BF-48FD-A480-C68B556E336BQ33449162-D75C866D-FE6E-4054-BA5D-1C5432BCB1FCQ33533366-D4F25D91-D7D3-43FA-8C19-7115262DB0B4Q34070485-EDBC877B-D35A-48C2-8AEA-F094FD5A4672Q34629219-A7F6EC89-3036-467C-910D-001656F5DD35Q34785683-049DCC77-383E-4028-B4BE-2E85B0D255DDQ34800507-DBB90FDE-1CC0-4B69-B50A-46CC435F3AE5Q35063655-15B08E0E-B5E2-4F79-B945-D6DD3EFAC966Q35095416-77DB2554-F31D-4A27-B457-701D60DA3AFDQ35866994-C0D37059-E25F-45AE-A4D3-338D52FB2375Q36276597-51A6B372-9D43-485A-A9FB-16AD642C50F3Q36286145-D4908557-D56A-4647-A4B9-A77DD2A327DAQ36663686-F5B3A8E0-D7AD-4AE7-BBE2-070536A60F7AQ36718901-2BC2F724-0246-46E0-BF68-4357EEDF14B1Q36871125-27F9B383-F069-42AB-AA13-533EFA56E814Q36945761-8291DA99-23FB-4D2D-891F-7613A2439F2BQ36984240-1A792694-DF1B-4D26-A9C7-130745CD74AEQ37161725-266AAD61-7982-4C4E-9717-EB75EB3D0902Q37357476-301CE9EB-55DA-4079-9BE1-5CD27C420DFEQ37699575-3672430C-B89E-4556-A12E-87F037EC4C9EQ38651617-2E50AF32-7D33-454D-9E68-4EAEC1E83BCEQ39164016-0EBFFAD9-8A31-48CB-872C-10E22EA8465DQ39842524-77C34F71-379A-45B6-AB2B-BEC35E1909F3Q43040666-13BF253D-BC9B-42C5-8F65-FF8BEFF8634BQ43498043-63FA165F-721A-4708-A350-BEFAE66BC06CQ45401707-ABC504B3-BAEB-411E-AB5C-DDEBDE4811CFQ45857827-6259BE60-FFF4-4F79-8C25-A7703393D300Q46082178-81551D87-4053-4B42-A8F2-7B98ADCAD8D5Q57880260-85787232-B642-4180-A5F0-41096C0E12B7
P2860
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Risk of severe hepatotoxicity ...... T Cohort, Thailand, 1996-2001.
@en
Risk of severe hepatotoxicity ...... T Cohort, Thailand, 1996-2001.
@nl
type
label
Risk of severe hepatotoxicity ...... T Cohort, Thailand, 1996-2001.
@en
Risk of severe hepatotoxicity ...... T Cohort, Thailand, 1996-2001.
@nl
prefLabel
Risk of severe hepatotoxicity ...... T Cohort, Thailand, 1996-2001.
@en
Risk of severe hepatotoxicity ...... T Cohort, Thailand, 1996-2001.
@nl
P2093
P1433
P1476
Risk of severe hepatotoxicity ...... T Cohort, Thailand, 1996-2001.
@en
P2093
Apicha Mahanontharit
Chris J Duncombe
David A Cooper
Gregory J Dore
Joep M A Lange
Mark A Boyd
Praphan Phanuphak
W Phillip Law
P304
P356
10.1097/00002030-200310170-00007
P407
P577
2003-10-01T00:00:00Z